News

Under this IND, Tolero intends to conduct a Phase 1/1b, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic and pharmacodynamic study, which will evaluate oral TP‑1454 alone, and in combination with

The approval allows Zolgensma to treat patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1or patients with

“We are pleased to offer people with certain types of lung cancer a new chemotherapy-free option that can help prolong their lives and be administered on a flexible

The company has reported positive interim clinical data of mRNA-1273 from the phase 1 study by the National Institute of Allergy and Infectious Diseases (NIAID), part of the

Can-Fite BioPharma, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced it has filed a pre-Investigational New

The FDA approval allows Qinlock, a kinase inhibitor, to treat adult patients with advanced GIST who have secured prior treatment with three or more kinase inhibitors, including imatinib.

Four metastatic pancreatic cancer patients have been treated with PD-L1 t-haNK and N-803 under single patient INDs, with two patients on treatment for an evaluable period. One patient reported

FDA Fast Track is a program designed to facilitate and expedite the development and review of a new drugs that demonstrates the potential to address an unmet medical

Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) that includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent monomethyl auristatin E (MMAE)